Source link : https://newshealth.biz/health-news/adc-post-endocrine-therapy-misses-mark-in-advanced-breast-cancer-trial/
(MedPage Today) — SAN ANTONIO — The antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) failed to outperform chemotherapy as first treatment after endocrine therapy for metastatic hormone receptor-positive/HER2-negative breast cancer… Source link : https://www.medpagetoday.com/meetingcoverage/sabcs/118963 Author : Publish date : 2025-12-11 20:07:00 Copyright for syndicated content belongs to the linked Source.
The post ADC Post-Endocrine Therapy Misses Mark in Advanced Breast Cancer Trial first appeared on News Health.
—-
Author : News Health
Publish date : 2025-12-11 20:07:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8